Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 03, 2021

SELL
$15.82 - $21.57 $11.5 Million - $15.6 Million
-724,873 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$20.3 - $31.75 $1.94 Million - $3.03 Million
-95,567 Reduced 11.65%
724,873 $14.7 Million
Q4 2020

Feb 17, 2021

BUY
$19.14 - $28.13 $15.7 Million - $23.1 Million
820,440 New
820,440 $21.8 Million
Q4 2020

Feb 16, 2021

SELL
$19.14 - $28.13 $15.7 Million - $23.1 Million
-820,440 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$22.4 - $24.47 $589,635 - $644,123
26,323 Added 3.31%
820,440 $17.7 Million
Q3 2020

Nov 16, 2020

BUY
$22.4 - $24.47 $17.8 Million - $19.4 Million
794,117 New
794,117 $17.1 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $89.5M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Sands Capital Management, LLC Portfolio

Follow Sands Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sands Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sands Capital Management, LLC with notifications on news.